Endocrine Abstracts

Interferon-alpha (IFNa) is used for the treatment of various disorders, including chronic hepatitis C virus (HCV) infection and certain malignancies. One of the commonest side effects of IFNa therapy is thyroiditis, with up to 40% of HCV patients on IFNa developing clinical or subclinical disease. In some cases interferon induced thyroiditis (IIT) may cause complications such as atrial fibrillation resulting in discontinuation of therapy. IIT can manifest clinically as thyroto...

Introduction: Major advances in the research and treatment of diabetes-related neuropathic phenomena are hampered due to its complicated pathophysiology and the scarcity of valid experimental models. The aim of this study was to establish novel systems facilitating monitoring and dissection of processes central to the development of diabetic neuropathy.Methods: In a non-invasive in vivo model, two-photon microscopy is used to detect and assess mec...

Objective: To study the baseline characteristics predicting hypogonadotropic hypogonadism (HH) persistence in men with macroprolactinoma following medical treatment with cabergoline.Design: Retrospective cohort study conducted in a tertiary pituitary center.Methods: Male patients diagnosed with macroprolactinoma and HH that received cabergoline treatment with subsequent prolactin normalization were included: men that achieved eugon...

Objective: To study the outcomeof menwith macroprolactinoma followingcabergoline treatment based on tumor size.Design: A retrospective cohort study using a single tertiary referral center registry.Methods: The study included 96 men with macroprolctinoma, aged 16–84 years (mean 47.3 years) treated from 1993 to 2019,for a mean follow-up of 7.5 years. The cohort was subdivided into 3 groups according to baseline adenoma diameter...

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease the degradation of low–density lipoprotein (LDL) receptors, thereby increasing the removal of LDL particles from the blood and significantly reducing LDL cholesterol levels by an average of 65%. Blom et al. showed changes in vitamin E, adrenocorticotropic hormone (ACTH), cortisol, total testosterone, and estradiol in EVOLOCUMAB (PCSK9 inhibitor)–treated patients 1. Ther...